Quillaja saponin extracts are used by the pharmaceutical industry, as precursors for the production of veterinary and human vaccine adjuvants (preclinical developments and clinical use), and also as ingredients for the formulation of reagents in blood diagnostic kits.
Desert King International (DKI), of San Diego, CA, has been the world’s largest producer of saponin extracts. For more than a decade, DKI has produced and supplied most of the precursors of QS-21-rich adjuvants used as raw material by the pharmaceutical industry.
As industry requirements increased, the company devoted an increasing amount of resources to ensure sourcing and meeting the high standards demanded by its pharmaceutical customers. The company has established a strong integrated supply chain that guarantees the production of the highest purity extracts.
Control systems and in-depth knowledge result in the most consistent Quillaja-based saponin extracts available globally. Years of experience and customer orientation combine to make DKI the preferred precursor supplier for QS-21.
Adjuvants are substances that are added to vaccines to help boost an immune response. Additionally, they reduce the demand for antigens used in the industrial production of vaccines.
Purified saponins from Quillaja saponaria Mol. have been used as ingredients for the formulation of vaccine adjuvants by the pharmaceutical industry; uses of such formulations prepared from purified saponins include applications of preclinical vaccines, and commercial vaccines for veterinary and human use.
A classic adjuvant formulation is based on cage-like spherical nanoparticles formed spontaneously by mixing purified quillay saponins with cholesterol and phospholipids; these nanoparticles are known as immunostimulant complexes (ISCOMs).
Most adjuvants on the market today (e.g. aluminum hydroxide) mainly activate the humoral immune response (antibodies). What distinguishes adjuvants formulated with Quillay’s saponins from other adjuvants is their ability to induce strong activation of humoral (essential for marking pathogen cells) and cellular responses using cytotoxic T cells (critical to eliminating pathogens in their intracellular phase of infection, where they are not susceptible to the humoral response.
Quillaja saponin-based adjuvants are found today in dozens of commercially available veterinary vaccines by the world’s largest vaccine manufacturers. In addition, more than 15 human vaccines ranging from oncology to infectious diseases are being studied utilizing Quillaja saponins.
Please click here for a link to Human Clinical Trials with GMP QS-21*.
*The QS-21 manufactured by Desert King Chile is currently offered as a non-GMP, preclinical material and has not been evaluated in clinical research.
* Desert King International offers QS-21 GMP manufactured by a contracted laboratory in the European Union.
Quillaja saponins as a diagnostic reagent:
• Used for diagnostic buffers for hemolytic analysis.
• High QS18 content; Stronger hemolytic process.
• Stable and highly purified products.
• Effective in low concentrations.
• 100% soluble in water.
Quillaja Saponin Fractions Available for Preclinical Research: